Mukherjee, Sudipto

Risk of hematologic malignancies after radioiodine treatment of well-differentiated thyroid cancer

Molenaar, R. J., Sidana, S., Radivoyevitch, T., Advani, A. S., Gerds, A. T., Carraway, H. E., Angelini, D., Kalaycio, M., Nazha, A., Adelstein, D. J., et al. (2018) · Journal of Clinical Oncology

Multiple and Secondary Primary CancersThyroid Cancer Diagnosis and Treatment

Cited by 154

Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib: A Phase 1b Randomized Clinical Trial

Jabbour, E., Oehler, V. G., Koller, P. B., Jamy, O., Lomaia, E., Hunter, A. M., Uspenskaya, O., Samarina, S., Mukherjee, S., Cortes, J. E., et al. (2025) · JAMA Oncology

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 33

Major adverse cardiovascular events (MACE) in cancer patients treated with tirzepatide compared to GLP-1 receptor agonists: A target trial emulation using real-world data.

Ashruf, O., Mushtaq, A., Lin, C. (.-T., Volk, M., Orozco, Z., Hundal, J., Safdar, A., Thompson, C., Karimi, S., Jain, A. G., et al. (2025) · Journal of Clinical Oncology

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 4